Orphai Therapeutics Acquired by Quince Therapeutics | Healthcare M&A Deal

Quince Therapeutics has completed the acquisition of Orphai Therapeutics, a pharmaceuticals business in California, for $187 million. Quince Therapeutics acquisitions bring Orphai’s clinical-stage pulmonary pipeline into its strategy, led by LAM-001, an inhaled rapamycin (mTOR inhibitor) program for rare lung diseases including PH-ILD and bronchiolitis obliterans syndrome post lung transplant. Orphai Therapeutics acquisition supports Quince’s pulmonary focus in South San Francisco, CA, with recent Phase 2 data informing planned studies. The merger acquisition is paired with a private placement of up to $187 million in gross proceeds, including $115 million upfront and up to about $72 million from warrant exercises, with financing expected to fund operations through end of 2028 and support Phase 2b PH-ILD initiation and additional milestones.